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Biologic therapies offer hope to many patients who previously had no effective treatment options for their 
disease.  Whether for treatment of thousands of patients with a rare genetic disease or a rare blood disorder or 
for millions of patients with cardiovascular disease or diabetes, the number of patients treated with approved 
biologic drugs continues to increase worldwide.  
 
The uninterrupted supply of these lifesaving medicines depends on the strong expertise and technical and 
scientific understanding of individuals from many disciplines – molecular genetics and cell biology, upstream 
and downstream scientists and engineers, bioanalytical scientists, process and plant design engineers, etc.  
  
As production technology and process knowledge has advanced, the opportunity to implement process 
intensification has likewise increased.  While there are many advantages to drug substance process 
intensification – including opportunities for improve costs – another advantage is the possibility for smaller drug 
substance manufacturing footprints. 
 
This talk will survey where the industry is heading as well as implementation of integrated continuous 
processing in a digitally-enabled facility designed for intensified drug substance processes.  
 
 
 
 
 
 
